Claim Ledger
42% answered
Did management answer the analysts?
12 analyst questions audited, 6 evaded or deflected.
View Claim Ledger →Cipla Ltd — Q3 FY26
Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY).
bearish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY). PAT of INR 676 crore included a one-time INR 276 crore labor code charge. U.S. revenue fell to $167 million as Lenalidomide tapered and lanreotide supply was disrupted (partner Pharmathen paused production after FDA observations; resupply expected H1 FY27). India business grew 10% YoY, with respiratory crossing INR 5,000 crore. FY26 EBITDA margin guidance revised to ~21%. Key upcoming U.S. launches (4 respiratory, 4 peptide assets) are expected to offset revenue declines, but near-term headwinds persist. Risk: lanreotide disruption may extend beyond H1 FY27 if remediation is delayed.
सिप्ला की तीसरी तिमाही का राजस्व पिछले साल के मुकाबले लगभग बराबर रहा, जो 7,074 करोड़ रुपये था। कंपनी का मुनाफा मार्जिन 17.7% रहा, जो उम्मीद से कम है। इसकी वजह जेनेरिक दवाओं की कम बिक्री और रिसर्च पर ज्यादा खर्च (बिक्री का 7%) है। शुद्ध मुनाफा 676 करोड़ रुपये रहा, जिसमें 276 करोड़ रुपये का एक बार का लेबर कोड खर्च शामिल है। अमेरिका में बिक्री घटकर 167 मिलियन डॉलर रह गई, क्योंकि लेनालिडोमाइड की बिक्री कम हुई और लैनरियोटाइड की आपूर्ति रुक गई। भारत में कारोबार 10% बढ़ा, और सांस की दवाओं की बिक्री 5,000 करोड़ रुपये पार कर गई। कंपनी ने सालाना मुनाफा मार्जिन का अनुमान घटाकर 21% कर दिया है। आने वाले समय में नई दवाओं के लॉन्च से बिक्री बढ़ने की उम्मीद है, लेकिन फिलहाल चुनौतियां बनी हुई हैं।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Lanreotide supply disruption may extend beyond H1 FY27
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
U.S. Revenue
$167M
-28% QoQ
Sequential decline from ~$233M in Q2 FY26, driven by Lenalidomide taper and lanreotide supply disruption.
India Business Growth
10%
+10% YoY
One India business delivered 10% YoY growth, with respiratory up 11% and chronic mix at 62.3%.
R&D Spend as % of Revenue
7%
+200bps YoY
R&D investment at INR 4,194 crore, up 37.4% YoY, driven by pipeline development and API purchases.
Lanreotide Resupply Timeline
H1 FY27
N/A
Production paused after FDA 483 observations; resupply expected in H1 FY27, causing short-term disruption.
What Changed vs Last Quarter
NEW
U.S. launches: 4 respiratory and 4 peptide assets in FY27
Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.
NEW
Lanreotide resupply expected in H1 FY27
Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway.
NEW
FY27 guidance to be provided next quarter
Management will provide FY27 guidance after finalizing the annual operating plan.
UPDATED
FY26 EBITDA margin guidance revised to ~21%
Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact.
DROPPED
Generic Revlimid contribution immaterial from Q3 FY26
Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.
DROPPED
Launch of four major respiratory assets by CY26
Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.
DROPPED
US revenue directional target of $1B next year
Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.
NEW RISK
Lanreotide supply disruption may extend beyond H1 FY27
Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.
NEW RISK
U.S. launch pipeline may face delays or competition
Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.
NEW RISK
Elevated R&D spend may persist, pressuring margins
R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.
NEW RISK
Semaglutide generic launch could impact tirzepatide uptake
Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive.
RISK GONE
Revlimid revenue cliff
Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
RISK GONE
Execution risk on US pipeline launches
Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
RISK GONE
India branded business growth slowdown
India branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.
RISK GONE
Tirzepatide exclusivity and competition
Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside.
🤫 Topics management stopped discussing
Mentioned in Q2 FY25, Q3 FY25, Q4 FY25
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Mentioned in Q1 FY26, Q3 FY25
Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.
Mentioned in Q2 FY26, Q4 FY25
Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
Mentioned in Q2 FY26, Q3 FY25
Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
Mentioned in Q1 FY25, Q2 FY25
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Fast read
Guidance and risk preview
Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact.
Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S.
View Risks →